About 


Our Mission 


Cellengene is biopharmaceutical company dedicated to the development for CAR-T therapy targeting refractory solid tumors. Our goal is to develop
"Off-the-Shelf" CAR-T therapy that can selectively attack cancer cells  using immune cell derived from healthy people. In order to cure pancreatic cancer, we plan to use gammadelta T cell and induced pluripotent stem cell (iPSC) platform. Furthermore, we will be enable to cure ovarian cancer, mesothelioma and will become a global company to help many patients who are suffering from refractory cancers.
We belive next generation CAR-T therapy will give hope to many patients and lead them to have happier and healthier life.
            


History


 
2021.11
▷ International patent application (Singapore)
2021.10
▷ International patent application (U.S, Japan, Europe, Australia, Canada, China)
2021.09
▷ Domestic patent acquisition
2021.01
▷ Headquarter relocation to Institut Pasteur Korea
2020.11
▷ Investment attraction from SJ Investment Partners
2020.10
▷ Selected as a Bio Core Facility construction project in Institut Pasteur Korea
2020.09
▷ Investment attraction from Soorim Venture Capital Co., Ltd.
▷ LMO Safety Management Level 2 Certificate
2020.07
▷ Selected as a TIPS-linked business (Start-up commercialization, overseas marketing)
2020.05
▷ Selected as TIPS (Accelerator Investment-Driven Tech Incubator Program for Startup)
▷ Attracting angel matching investment from Korea Venture Investment Co., Ltd.
▷ Designated as Seoul Bio Hub All-In-One (Selection of mentor consulting support project)
▷ Approval of pre-sale to the National Stem Cell Bank under the National Institute of Health
2019.12
▷ Acquired Kingsley Ventures Inc. VC funding
▷ Venture company Certification
2019.11
▷ Moved into Seoul Biohub
▷ Small business Certification
▷ Established enterprise affiliated research institute
▷ Commissioned research agreement with Osong Medical Innovation Foundation (K-Bio)
2019.06
▷ Established Cellengene Inc.
2019.04
▷ Biohealth Innovation Start-up Members (Moved into Yonsei Bongrae Building)

 CAR-T Therapy



CAR-T therapy is one of the immunotherapy, including genetically modifed T cell expressing unique receptor "Chimeric Antigenic Receptor" .  This unique receptor binds to certain protein on patient's cancer cells and selectively attack them.  In current situation, FDA approval were granted to 5 types of treatment targeting hematological malignancies, including “Kymriah” from Novartis and “Yescarta” from Gilead.  There are many ongoing researches, developments and clinical stages on CAR-T therapy but no succeed case appears yet.


 


In general, there are two ways to manufacture CAR-T therapy.  Autologous CAR-T  is personalized therapy that does not incur GvHD.  Because it is  derived from patient's own cell and reinjected to the patient. However, manufacturing process takes at least 3 weeks and costs are very expensive. Allogenic CAR-T is universial therapy that require genetically engineering process and mass production is available. Manufacturing process takes approximately 1 week and costs are lower than autologous CAR-T production. Therefore, immediate injection is available for hundreds of patients. 


CAR-T Platform


 

 

 

Genome Editing Technology


Preventing GvHD and overcoming tumor microenvironment(TME) are key factors to develop allogenic CAR-T therapy. In order to overcome these certain problems, TCR is knockout using CRISPER/CAS9 gene editing technology and immune check receptor, PD-1, is  knockdown to induce T cell activation and attack cancer cell continuously. 

 

 Induced Pluripotent Stem Cell (iPSC)


iPSC technology is capable of unlimiting T cell expansion and producing homogenous differentiated T cell. It provides high purity with massive amounts of production of allogenic T cell. Therefore, manufacturing cost is low and less-time consuming.

News


Beautiful design and layout...
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus et nisl ex. Maecenas dignissim volutpat efficitur. Nullam hendrerit dui mattis sapien pulvinar blandit.
  • Mieke Visser
  • category
  • now
  • 1
  • 15
7
Excellent work! Great presentation!
Quisque ut urna tempus, aliquam libero vitae, viverra lacus. Nunc dictum viverra elit, sed tincidunt turpis tincidunt vel.
  • Suraj Gajjar
  • category
  • 5 hour ago
  • 25
  • 7
6
Awesome work..really very inspirational job
Etiam ut sapien mauris. Nullam molestie elit sem, accumsan lacinia eros condimentum in. Morbi varius turpis in sapien rhoncus, at sagittis massa accumsan.
  • Jit Pandkar
  • category
  • 3 days ago
  • 142
  • 7
5
Aenean malesuada non libero a auctor
Vivamus sollicitudin leo quis suscipit cursus. Fusce tristique justo vitae risus elementum, sit amet maximus lectus finibus. Vivamus tristique tristique turpis. Vivamus quam mi, imperdiet ac orci id, facilisis dictum massa Nunc condimentum molestie risus. Nullam mollis quam...
  • Den Kdivinich
  • category
  • dev 22
  • 187
  • 7
4
Phasellus et nisl
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus et nisl ex. Maecenas dignissim volutpat efficitur. Nullam hendrerit dui mattis sapien pulvinar blandit.
  • James Kyriakou
  • category
  • dev 7
  • 58
  • 7
3
Etiam ut sapien mauris
Quisque ut urna tempus, aliquam libero vitae, viverra lacus. Nunc dictum viverra elit, sed tincidunt turpis tincidunt vel. Praesent eget metus sapien. Maecenas viverra quam justo, eu rhoncus elit congue non.
  • James Kyriakou
  • category
  • nov 31
  • 69
  • 7
2
Excellent work! Great presentation!
Etiam ut sapien mauris. Nullam molestie elit sem, accumsan lacinia eros condimentum in. Morbi varius turpis in sapien rhoncus, at sagittis massa accumsan.
  • Mieke Visser
  • category
  • nov 17
  • 81
  • 7
1
Beautiful design and layout...
Vivamus sollicitudin leo quis suscipit cursus. Fusce tristique justo vitae risus elementum, sit amet maximus lectus finibus. Vivamus tristique tristique turpis. Vivamus quam mi, imperdiet ac orci id, facilisis dictum massa Nunc condimentum molestie risus. Nullam mollis quam...
  • Den Kdivinich
  • category
  • nov 2
  • 114
  • 7

Notice 

no category title name date view
category Frequently asked question about this pages and delevery process while ordered post didn't arrive 7 admin now 50
9 category Good design.I will be glad if you see my latest work. Jack 5 hour ago 175
8 category awesome work..really very inspirational job.congrats David James 3 days ago 534
7 category Beautiful design and layout.. Great job BaByliss dev 22 51
6 category Amazing work one really feels like in a stone age. Impressive! Oliver Warren dev 7 235
5 category Unbelievable divat not dive project itself is awesome but it's presentation here... congratulations! DIANA nov 31 165
4 category Excellent work! Great presentation! Jett nov 18 25
3 category od design.I will be glad if you see my latest work. Lincoln nov 17 266
2 category Beautiful design and layout.. Great job Blaise nov 13 369
1 category Amazing work one really feels like in a stone age. Impressive! Raphael nov 4 16

Career 


E.  contact@cellengene.com
T.  (+82) 2-966-2676

INQUIRY FOR JOB POSITIONS

SEND MESSAGE



Contact


Headquarter

3rd Floor, Research Building, Institut Pasteur Korea                                                   16 Daewangpangyo-ro 712 beon-gil, Bundang-gu, Seongnam-si,                        
Gyeonggido, Korea, 13488   

R&D Center

Research Building Rm 204, Seoul Bio Hub
117-3 Hoegi-ro, Dongdaemun-gu, Seoul,
Republic of Korea, 02455

TEL

(+82) 2-966-2676

FAX

(+82) 2-6442-5756

E-mail

contact@cellengene.com

SEND MESSAGE